An FDA advisory committee on Wednesday unanimously voted against recommending approval of the PARP inhibitor talazoparib ...

As of this writing, the role of PD-L1 inhibitors in prostate cancer remains limited to a subset of patients with metastatic microsatellite instability-high, mismatch repair-deficient, or tumor ...

The results of this phase III KEYNOTE-991 study do not support the addition of pembrolizumab to enzalutamide and ADT for the treatment of mHSPC,” researchers wrote.

The combination of enzalutamide with androgen deprivation therapy (ADT) significantly increases the chance of five-year survival for men with metastatic hormone-sensitive prostate cancer, according to ...

Discover a study that also highlighted that treatment intensification with enzalutamide benefited patients regardless of ...

Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30% After a median follow-up of 61.4 months ...

Modulation of enhancer of zeste homolog 2 (EZH2) pharmacodynamic (PD) markers and tumor gene expression by mevrometostat in combination with enzalutamide in patients with castration-resistant prostate ...

A randomized phase III trial investigating platinum and taxane chemotherapy in metastatic castration resistant prostate cancer (mCRPC) patients with alterations in DNA damage response (DDR) genes ...

The FDA approved the poly ADP ribose polymerase (PARP) inhibitor in June 2023 in combination with enzalutamide for men with ...